UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.

Saved in:
Bibliographic Details
Title: UCPVax, a CD4 helper peptide vaccine, induces polyfunctional Th1 cells, antibody response, and epitope spreading to improve antitumor immunity.
Authors: Laheurte C; Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France., Boullerot L; Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France., Ndao B; Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France., Malfroy M; Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France., Queiroz L; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland., Guillaume P; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland., Loyon R; Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France., Seffar E; Computational Oncology Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA., Gravelin E; Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France., Renaudin A; Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France., Jacquin M; Clinical Investigational Center, CIC-1431, Centre Hospitalier Universitaire de Besançon, Besançon, France., Meurisse A; Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France., Vernerey D; Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France; Methodology and Quality of Life in Oncology Unit, University Hospital of Besançon, Besançon, France., Ghiringhelli F; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France., Godet Y; Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France., Genolet R; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland; Department of Oncology UNIL CHUV, University Hospital of Lausanne, Lausanne, Switzerland., Jandus C; Ludwig Institute for Cancer Research, Lausanne Branch, University of Lausanne and Lausanne University Hospital, Lausanne, Switzerland; Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, Geneva, Switzerland; Geneva Center for Inflammation Research, Geneva, Switzerland., Borg C; Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France; Clinical Investigational Center, CIC-1431, Centre Hospitalier Universitaire de Besançon, Besançon, France; Department of Medical Oncology, University Hospital of Besançon, 25000 Besançon, France., Adotévi O; Université Marie et Louis Pasteur, EFS, INSERM, UMR RIGHT, 25000 Besançon, France; Department of Medical Oncology, University Hospital of Besançon, 25000 Besançon, France. Electronic address: olivier.adotevi@univ-fcomte.fr.
Source: Cell reports. Medicine [Cell Rep Med] 2025 Jul 15; Vol. 6 (7), pp. 102196. Date of Electronic Publication: 2025 Jun 20.
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article; Multicenter Study
Journal Info: Publisher: Cell Press Country of Publication: United States NLM ID: 101766894 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2666-3791 (Electronic) Linking ISSN: 26663791 NLM ISO Abbreviation: Cell Rep Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2666-3791
DOI:10.1016/j.xcrm.2025.102196